BRCA2 and cancer: Western blot analysis of cells 48 h after treatment with cediranib revealed decreases in BRCA1, BRCA2, and RAD51 expression (Fig. 4C, with replicates shown in Supplementary Fig. S4), consistent with prior work in multiple other cancer cell lines [32], and supporting the proposed mechanism of synthetic lethality.